BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amgen (AMGN) Chooses Freeslate as Strategic Partner for Protein Drug Product R&D


10/20/2011 12:15:06 PM

Sunnyvale, Calif. (PRWEB) October 20, 2011 -- Freeslate, Inc., the leading provider of high throughput research solutions, announced today that Amgen, Inc. has entered into a collaborative relationship with the company to leverage Freeslate solutions in addressing aggregation and particulation in protein drug products. The multi-year project will utilize a range of Freeslate products and services, including technology development, high throughput microscale workflows, and Freeslate’s Lab Execution and Analysis (LEA) software.

Freeslate was selected by Amgen for its depth of knowledge and experience in implementing solutions for solving the complex protein formulation challenges Amgen is facing. A tenured leader in the area of high throughput research, Freeslate has built strong capabilities around automated solutions addressing the complex problems of drug development and enabling dramatic gains in R&D productivity and innovation.

Freeslate’s integrated workflows are managed by its LEA software platform which creates a single, experimental environment that helps to accelerate scientific decision making and QbD initiatives.

“As illustrated by this relationship and others we have engaged in over the past year, the formulation of protein therapeutics is a pressing problem for pharmaceutical companies. High throughput research can enable significant steps forward in both understanding and addressing the challenges of aggregation and particulation in protein drug products,” said John Senaldi, CEO of Freeslate. “This is an application area where we are confident in our ability to deliver great value and innovation.”

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, energy, and consumer products industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe and Asia. For more information, visit http://www.freeslate.com.



Read at BioSpace.com

Freeslate
Amgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES